Novo Nordisk AS (NVO)
105.06
+2.43
(+2.37%)
USD |
NYSE |
Nov 22, 16:00
105.08
+0.02
(+0.02%)
Pre-Market: 20:00
Novo Nordisk Cash from Operations (Quarterly): 6.658B for Sept. 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 6.658B |
| June 30, 2024 | 7.271B |
| March 31, 2024 | 2.085B |
| December 31, 2023 | 1.302B |
| September 30, 2023 | 5.975B |
| June 30, 2023 | 4.234B |
| March 31, 2023 | 4.300B |
| December 31, 2022 | 1.464B |
| September 30, 2022 | 2.912B |
| June 30, 2022 | 3.249B |
| March 31, 2022 | 3.558B |
| December 31, 2021 | -446.39M |
| September 30, 2021 | 3.281B |
| June 30, 2021 | 4.092B |
| March 31, 2021 | 1.825B |
| December 31, 2020 | -174.18M |
| September 30, 2020 | 3.073B |
| June 30, 2020 | 3.583B |
| March 31, 2020 | 1.478B |
| December 31, 2019 | 815.04M |
| September 30, 2019 | 2.449B |
| June 30, 2019 | 2.245B |
| March 31, 2019 | 1.505B |
| December 31, 2018 | 1.266B |
| September 30, 2018 | 1.702B |
| Date | Value |
|---|---|
| June 30, 2018 | 2.480B |
| March 31, 2018 | 1.619B |
| December 31, 2017 | 713.69M |
| September 30, 2017 | 2.268B |
| June 30, 2017 | 1.552B |
| March 31, 2017 | 1.733B |
| December 31, 2016 | 1.609B |
| September 30, 2016 | 2.237B |
| June 30, 2016 | 2.230B |
| March 31, 2016 | 1.105B |
| December 31, 2015 | 1.501B |
| September 30, 2015 | 1.814B |
| June 30, 2015 | 1.759B |
| March 31, 2015 | 621.90M |
| December 31, 2014 | 1.315B |
| September 30, 2014 | 2.096B |
| June 30, 2014 | 1.494B |
| March 31, 2014 | 746.96M |
| December 31, 2013 | 963.64M |
| September 30, 2013 | 1.141B |
| June 30, 2013 | 1.263B |
| March 31, 2013 | 1.251B |
| December 31, 2012 | 361.06M |
| September 30, 2012 | 1.276B |
| June 30, 2012 | 1.214B |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-446.39M
Minimum
Dec 2021
7.271B
Maximum
Jun 2024
3.027B
Average
3.161B
Median
Cash from Operations (Quarterly) Benchmarks
| Ascendis Pharma AS | -- |
| Amgen Inc | 3.571B |
| AstraZeneca PLC | 3.383B |
| Viking Therapeutics Inc | -21.96M |
| Evaxion Biotech AS | -- |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -3.131B |
| Cash from Financing (Quarterly) | -2.741B |
| Free Cash Flow | 9.828B |
| Free Cash Flow Per Share (Quarterly) | 1.064 |
| Free Cash Flow to Equity (Quarterly) | 4.406B |
| Free Cash Flow to Firm (Quarterly) | 4.748B |
| Free Cash Flow Yield | 2.09% |